DMD drug trial shows regulatory flexibility is possible for rare diseases

Mindy Leffler, whose son has Duchenne muscular dystrophy (DMD), wrote an opinion piece arguing for regulatory flexibility in rare disease drug trials. She points to the Capricor Therapeutics' Duchenne drug trial as an example where small study design decisions made a big difference, showing rigor doesn't have to be sacrificed.